Bluejay Diagnostics Completes Commercial Production of IL-6 Antibodies

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Dec 29 2025

0mins

Should l Buy BJDX?

Bluejay Diagnostics completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6, a biomarker relevant to inflammatory and critical-care applications. The Company stated that both polyclonal and monoclonal antibodies met internal performance criteria, including reactivity, for use in Symphony cartridge manufacturing intended for clinical and potential future commercial applications. Bluejay has generated polyclonal antibodies using both third-party and internally developed immunogens. The Company intends to utilize antibodies produced from its proprietary immunogen for ongoing development activities in support of its intellectual-property strategy. The monoclonal antibodies produced by the Company, designated for use as detection antibodies in the IL-6 assay, have demonstrated acceptable binding, specificity, and signal performance characteristics for their intended diagnostic use, based on internal testing conducted to date. Based on current antibody inventory, Bluejay estimates that it has sufficient material to support production of more than nine million Symphony cartridges for clinical and commercial manufacturing purposes. The Company has also established the capability to produce additional antibodies as needed.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy BJDX?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on BJDX

About BJDX

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Bluejay Diagnostics Enrolls 545 Patients in SYMON™ II Study

2 days agoNewsfilter

Clinical Trial Progress: Bluejay Diagnostics has successfully enrolled 545 patients in its SYMON™ II multicenter IL-6 monitoring study, exceeding initial expectations with a target of 750 patients, demonstrating strong execution in clinical recruitment, which reduces execution risk and prepares for subsequent data analysis and commercialization.
Manufacturing Readiness: The company is advancing manufacturing readiness across multiple parallel workstreams, including antibody production and commercial manufacturing infrastructure, having completed monoclonal and polyclonal antibody production sufficient for over 10 million test cartridges, ensuring supply capacity for U.S. market production.
Technology Transfer Progress: Technology transfer activities are progressing without a single point of failure, with management employing parallel execution strategies to mitigate timing and scale-up risks, ensuring the smooth advancement of the SYMON™ II program.
Future Outlook: As Bluejay enters 2026, management believes the company is operating from a materially stronger execution position with reduced clinical risk, focusing on value realization through data analysis and regulatory engagement to further drive commercialization readiness.

Etsy Sells Depop to eBay for $1.2 Billion

5 hours agoBenzinga

Significant Transaction Value: Etsy has entered into a definitive agreement with eBay to sell its fashion marketplace Depop for approximately $1.2 billion in cash, which not only provides Etsy with substantial cash flow but also enhances its financial flexibility to support future strategic investments.
Stock Price Surge: Etsy's shares jumped 15.5% to $50.86 in pre-market trading, reflecting a positive market reaction to the deal and increasing investor confidence in the company's future growth potential.
Market Consolidation Trend: This transaction signifies further consolidation in the e-commerce sector, as eBay's acquisition of Depop will expand its influence in the fashion market, while Etsy can focus on its core business to improve operational efficiency.
Strategic Focus Shift: By selling Depop, Etsy can reallocate resources to concentrate on growth within its primary platform, with expectations to drive long-term profitability through optimizing product lines and enhancing user experience.

Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split

Jan 27 2026seekingalpha

Reverse Stock Split Announcement: Bluejay Diagnostics has announced a 1-for-4 reverse stock split effective January 29, which will reduce its outstanding shares from approximately 2.83 million to about 708,533, aimed at increasing share price to meet listing requirements.
Stock Price Reaction: Following the reverse split announcement, Bluejay's shares fell 2.66% in pre-market trading to $0.77, indicating market concerns regarding the company's financial health, which could impact investor confidence.
New CUSIP Number: The new CUSIP number for Bluejay's shares post-split will be 095633608, facilitating investor identification of the stock and ensuring smooth trading operations.
Cash Payment for Fractional Shares: The company will provide cash payments to shareholders in lieu of any fractional shares resulting from the reverse split, a measure designed to mitigate potential losses for shareholders and protect their interests.